Physician profile
Michael Frances Payment
NPI 1760496475
$16,449.47
in general payments reported to CMS, 2019-2025
44 companies · $2,777 in 2025
The $2,777 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $1,504 · 2021: $2,858 · 2022: $3,057 · 2023: $2,014 · 2024: $2,305 · 2025: $2,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,119 · Travel and Lodging: $897 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,119.15 |
| Travel and Lodging | $896.70 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,510.54 | 2019-2025 | |
| Abbott Laboratories | $1,344.87 | 2019-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $1,219.35 | 2021-2025 | Impella |
| Cvrx, INC. | $1,135.41 | 2024-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $937.21 | 2019-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $891.66 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $876.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $833.97 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $803.12 | 2019-2025 | Watchman Access System, Watchman, Cds - Mct/Cem Monitoring |
| Shockwave Medical, INC | $742.77 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $737.92 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $710.26 | 2019-2025 | Jardiance |
| Amgen INC. | $557.06 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $551.66 | 2021-2025 | Corevalve Evolut R, Micra |
| Esperion Therapeutics, INC. | $522.13 | 2020-2024 | Nexletol |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Payment listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.